In yesterday’s Wall Street session, Taysha Gene Therapies Inc. (NASDAQ:TSHA) shares traded at $3.28, down -2.96% from the previous session.
As we calculate the median target price by taking the range between a high of $8.00 and a low of $2.00, we find $6.00. Given the previous closing price of $3.38, this indicates a potential upside of 77.51 percent. TSHA stock price is now 213.94% away from the 50-day moving average and 164.79% away from the 200-day moving average. The market capitalization of the company currently stands at $646.09M.
Brokers who have rated the stock have averaged $5.72 as their price target over the next twelve months.
With the price target reduced from $14 to $1.50, Jefferies Downgraded its rating from Buy to Hold for Taysha Gene Therapies Inc. (NASDAQ: TSHA).
In other news, Alam Kamran, Chief Financial Officer sold 33,000 shares of the company’s stock on Aug 24. The stock was sold for $76,890 at an average price of $2.33. Upon completion of the transaction, the Chief Financial Officer now directly owns 258,042 shares in the company, valued at $0.85 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 16, 10% Owner Manning Paul B bought 16,466,667 shares of the business’s stock. A total of $14,820,000 was incurred on buying the stock at an average price of $0.90. This leaves the insider owning 16,466,667 shares of the company worth $54.01 million. Insiders disposed of 549,095 shares of company stock worth roughly $1.8 million over the past 1 year. A total of 3.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TSHA stock. A new stake in Taysha Gene Therapies Inc. shares was purchased by SQUAREPOINT OPS LLC during the first quarter worth $264,000. DYNAMIC ADVISOR SOLUTIONS LLC invested $148,000 in shares of TSHA during the first quarter. In total, there are 61 active investors with 23.20% ownership of the company’s stock.
During the past 12 months, Taysha Gene Therapies Inc. has had a low of $0.50 and a high of $4.06. The fifty day moving average price for TSHA is $1.0965 and a two-hundred day moving average price translates $1.2454 for the stock.
The latest earnings results from Taysha Gene Therapies Inc. (NASDAQ: TSHA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.31 by -0.07. This compares to -$0.85 EPS in the same period last year. For the current quarter, analysts expect TSHA to generate $1.32M in revenue.
